5-Amino-1MQ vs PT-141 (Bremelanotide)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

5-Amino-1MQPT-141 (Bremelanotide)
CategoryPeptidesPeptides
Standard DoseResearch indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.
TimingMorning dosing preferred. Can be taken with or without food.45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.
Cycle Duration8-12 week cycles.As-needed basis. Not intended for daily use.
Evidence Levelanimal_plus_anecdotalstrong_human
A

5-Amino-1MQ

Peptides

Mechanism

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA). By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, reduces 1-MNA production, suppresses lipogenesis in adipocytes, and modulates the methionine-homocysteine cycle. In vivo, it significantly reduces body weight, white adipose mass, and adipocyte size through enhanced energy expenditure and altered lipid metabolism.

Standard Dosing

Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.

Timing

Morning dosing preferred. Can be taken with or without food.

Cycle Duration

8-12 week cycles.

Side Effects

  • Mild GI discomfort
  • Headache
  • Diarrhea (uncommon)
  • Nausea at higher doses

Contraindications

  • Pregnancy and breastfeeding
  • Severe hepatic impairment
  • Active cancer (NAD+ modulation concern)

Best Stacking Partners

MOTS-cAOD-9604TesofensineSemaglutide

Mechanism

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin analog that acts as an agonist at MC3R and MC4R melanocortin receptors, with higher affinity for MC4R. It enhances sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release — an excitatory neurotransmitter for sexual desire. Unlike PDE5 inhibitors, PT-141 works centrally through the CNS rather than peripherally on blood flow, addressing desire rather than just erectile mechanics.

Standard Dosing

Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.

Timing

45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.

Cycle Duration

As-needed basis. Not intended for daily use.

Side Effects

  • Nausea (most common, dose-dependent)
  • Flushing
  • Headache
  • Nasal congestion (intranasal route)
  • Transient blood pressure increase
  • Skin darkening with repeated use

Contraindications

  • Uncontrolled hypertension
  • Cardiovascular disease
  • Pregnancy and breastfeeding
  • Use of other melanocortin agonists concurrently

Best Stacking Partners

Kisspeptin-10Melanotan II

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →